Creatine Kinase-MB

Gurmukh Singh, Paramdeep S. Baweja

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To evaluate the clinical utility of and demand for the creatine kinase (CK)-MB assay. Methods: We examined the number of CK-MB tests from 2007 through 2013 while we progressively deemphasized their use. We first removed CK-MB from the acute coronary syndrome (ACS) panel and then from the main menu and observed the demand for the test. We also reviewed patient medical records to assess the appropriateness of its use. Results: After removing CK-MB from the ACS panel, the test volume dropped from around 12,000 per year to about 150 per year. In reviewing the records of 171 patients who had CK-MB determination done over a 28-month period, we discovered that CK-MB contributed to the diagnosis in only one patient, although it was not essential. Since removing CK-MB from the laboratory menu, two CK-MB tests were ordered in 4 months, and neither added value. Conclusions: CK-MB determinations do not add value to information available from the troponin assay and can be safely removed from the laboratory menu.

Original languageEnglish (US)
Pages (from-to)415-419
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume141
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

MB Form Creatine Kinase
Acute Coronary Syndrome
Troponin
Medical Records

Keywords

  • Acute coronary syndrome
  • CK-MB
  • Obsolete laboratory tests
  • Troponin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Creatine Kinase-MB. / Singh, Gurmukh; Baweja, Paramdeep S.

In: American Journal of Clinical Pathology, Vol. 141, No. 3, 01.03.2014, p. 415-419.

Research output: Contribution to journalArticle

Singh, Gurmukh ; Baweja, Paramdeep S. / Creatine Kinase-MB. In: American Journal of Clinical Pathology. 2014 ; Vol. 141, No. 3. pp. 415-419.
@article{ba5476810f024f37917d091a047b5c69,
title = "Creatine Kinase-MB",
abstract = "Objectives: To evaluate the clinical utility of and demand for the creatine kinase (CK)-MB assay. Methods: We examined the number of CK-MB tests from 2007 through 2013 while we progressively deemphasized their use. We first removed CK-MB from the acute coronary syndrome (ACS) panel and then from the main menu and observed the demand for the test. We also reviewed patient medical records to assess the appropriateness of its use. Results: After removing CK-MB from the ACS panel, the test volume dropped from around 12,000 per year to about 150 per year. In reviewing the records of 171 patients who had CK-MB determination done over a 28-month period, we discovered that CK-MB contributed to the diagnosis in only one patient, although it was not essential. Since removing CK-MB from the laboratory menu, two CK-MB tests were ordered in 4 months, and neither added value. Conclusions: CK-MB determinations do not add value to information available from the troponin assay and can be safely removed from the laboratory menu.",
keywords = "Acute coronary syndrome, CK-MB, Obsolete laboratory tests, Troponin",
author = "Gurmukh Singh and Baweja, {Paramdeep S.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1309/AJCPBIK3G4BWEJKO",
language = "English (US)",
volume = "141",
pages = "415--419",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Creatine Kinase-MB

AU - Singh, Gurmukh

AU - Baweja, Paramdeep S.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Objectives: To evaluate the clinical utility of and demand for the creatine kinase (CK)-MB assay. Methods: We examined the number of CK-MB tests from 2007 through 2013 while we progressively deemphasized their use. We first removed CK-MB from the acute coronary syndrome (ACS) panel and then from the main menu and observed the demand for the test. We also reviewed patient medical records to assess the appropriateness of its use. Results: After removing CK-MB from the ACS panel, the test volume dropped from around 12,000 per year to about 150 per year. In reviewing the records of 171 patients who had CK-MB determination done over a 28-month period, we discovered that CK-MB contributed to the diagnosis in only one patient, although it was not essential. Since removing CK-MB from the laboratory menu, two CK-MB tests were ordered in 4 months, and neither added value. Conclusions: CK-MB determinations do not add value to information available from the troponin assay and can be safely removed from the laboratory menu.

AB - Objectives: To evaluate the clinical utility of and demand for the creatine kinase (CK)-MB assay. Methods: We examined the number of CK-MB tests from 2007 through 2013 while we progressively deemphasized their use. We first removed CK-MB from the acute coronary syndrome (ACS) panel and then from the main menu and observed the demand for the test. We also reviewed patient medical records to assess the appropriateness of its use. Results: After removing CK-MB from the ACS panel, the test volume dropped from around 12,000 per year to about 150 per year. In reviewing the records of 171 patients who had CK-MB determination done over a 28-month period, we discovered that CK-MB contributed to the diagnosis in only one patient, although it was not essential. Since removing CK-MB from the laboratory menu, two CK-MB tests were ordered in 4 months, and neither added value. Conclusions: CK-MB determinations do not add value to information available from the troponin assay and can be safely removed from the laboratory menu.

KW - Acute coronary syndrome

KW - CK-MB

KW - Obsolete laboratory tests

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=84897944144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897944144&partnerID=8YFLogxK

U2 - 10.1309/AJCPBIK3G4BWEJKO

DO - 10.1309/AJCPBIK3G4BWEJKO

M3 - Article

C2 - 24515770

AN - SCOPUS:84897944144

VL - 141

SP - 415

EP - 419

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -